251 results about "Molecular imaging" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

The invention discloses a nanometer delivery device for a gastric cancer targeted drug and a use method of the nanometer delivery device, and belongs to the technical field of drug targeted delivery. The device comprises a molecular recognition and optimization module which is responsible for accurately recognizing a tumor cell specific molecular marker and providing personalized treatment strategy recommendation; the nano-carrier design module is used for designing multifunctional lipid-polymer hybrid nano-particles and carrying out surface targeting ligand modification; the intelligent drug loading module is used for improving the stability and controllability of drug loading based on a pH / temperature sensitive release mechanism and effectively reducing the toxic influence of non-targeted tissues; the molecular imaging and monitoring module integrates a nanoprobe imaging technology and a quantum dot tracing technology, constructs a treatment-imaging integrated system, realizes real-time dynamic monitoring of a treatment process, and provides instant feedback of a molecular level; and the risk assessment module is used for establishing a safety database and providing dynamic risk assessment of the treatment process through a biological safety assessment system and long-term tracking management.

Systems and methods include acquisition of an anatomical image of an object, acquisition of molecular imaging data of the object at the plurality of photon detectors, reconstruction of a functional image based on the molecular imaging data, input of the anatomical image and the functional image to a trained neural network to generate a second functional image, and presentation of the second functional image.

The invention relates to the field of molecular imaging, in particular to a molecular probe targeting GPC3. The invention claims to protect a molecular probe targeting GPC3, the molecular probe is a compound having the following sequence, or a pharmaceutically acceptable salt or ester thereof: (GPC3 antibody, including antibody fragment of GPC3 antibody, or single domain antibody thereof) m-Rn, where R is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, monoclonal antibody fragment, single domain antibody, and Rn is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, a monoclonal antibody fragment, and a single domain antibody. And a group consisting of small molecule inhibitors; wherein n represents the number of R, and n is equal to 0-4; wherein m is not 0. The probe has good in-vitro stability, can be clearly developed in tumors, and has good specificity.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

A method for molecular image acquisition includes beginning acquisition of a molecular image via a molecular imaging system, performing one or more analyses of the molecular image during acquisition of the molecular image to determine whether at least one hot spot is present in the image, and if it is determined that it is statistically significant that there is either at least one hot spot present or there is not at least one hot spot present in the image in any one of the one or more analyses of the molecular image, performing at least one of providing a recommendation that the acquisition be stopped or stopping the acquisition automatically.

The present invention relates to the field of molecular imaging, nuclear medicine and single-domain antibody technology for tumor diagnosis and treatment, and in particular to a method for preparing a radionuclide-labeled Trop2-specific single-domain antibody probe and its application. The Trop2-specific single-domain antibody has a CDR1 having an amino acid sequence shown in SEQ ID No.1, a CDR2 having an amino acid sequence shown in SEQ ID No.2, and a CDR3 having an amino acid sequence shown in SEQ ID No.3. The Trop2-specific single-domain antibody prepared by the present invention 18 The F-labeled single-domain antibody probe is used for immuno-PET imaging, which realizes the non-invasive visualization of Trop2 in vivo and further realizes the non-invasive diagnosis of Trop2-positive tumors. The probe has the advantages of simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical transformation.

The present invention discloses a CD47-specific molecular imaging probe and its preparation method and application, which relates to the molecular imaging, nuclear medicine and nano-antibody technology fields of tumor diagnosis and treatment, including human CD47-specific monovalent nano-antibody probes and human CD47-specific nano-antibody fusion protein probes; its preparation method comprises: modifying CD47-specific nano-antibody C2 by compounds, synthesizing radionuclide labeling precursors, and preparing the CD47-specific molecular imaging probe by radionuclide labeling; the prepared probe is applied to immune PET imaging and radioimmunotherapy of malignant tumors. The present invention has the advantages of simple preparation process, low cost, high specificity, high stability, and easy clinical transformation. It can realize non-invasive visualization of heterogeneous expression of CD47, screen patients with high expression of CD47, and further carry out CD47-specific radioimmunotherapy, that is, realize integrated diagnosis and treatment.

Systems and methods include determination of an anatomical image of an object, input of the anatomical image to a trained neural network to generate a synthetic functional image, acquisition of molecular imaging data of the object based on acquisition parameters, reconstruction of a functional image based on the molecular imaging data, determination of a difference between the functional image and the synthetic functional image, change of one of the acquisition parameters based on the difference, acquisition of second molecular imaging data of the object based on the changed acquisition parameters, and reconstruction of a second functional image based on the second molecular imaging data.

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The invention relates to an oxidase response type molecular probe as well as a preparation method and application thereof, and belongs to the technical field of medical imaging. Aiming at the problem that the inflammation activity is difficult to accurately evaluate in the prior art, the invention provides a molecular imaging probe capable of responding to the activity of in-vivo myeloperoxidase (MPO), and the molecular imaging probe can be used for real-time and non-invasive imaging monitoring of the activity of the in-vivo MPO, so that the activity of the inflammatory reaction of a focus is accurately evaluated. The invention provides a chelating agent with structural characteristics of a chelating unit and an enzyme response unit, and is characterized in that the enzyme response molecular probe is constructed by taking rigid framework cyclohexanediamine (CDTA) as a transition metal chelating unit and taking electron-rich functional groups (such as phenol, catechol or 5-hydroxytryptamine) as the enzyme response unit. The probe is chelated with paramagnetic metal (such as Mn < 2 + >) for magnetic resonance imaging (MRI) or radioactive metal (such as 68Ga) for positron emission tomography (PET), so that specific response to MPO activity is realized. The dynamic stability of the probe is remarkably improved; after the MPO is responded, the relaxation efficiency is improved by 2-3 times, and the sensitivity is optimized; the cytotoxicity is low; in an acute pancreatitis model, the MRI contrast noise ratio (delta CNR) reaches 77.39 + / -7.04 and is 4.2 times that of a control group, the PET uptake rate is remarkably improved, bimodal imaging is supported, and accurate positioning and quantitative evaluation of the inflammation activity are achieved.

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses a living blood vessel and lymph multi-parameter quantitative photoacoustic microscopic imaging system which comprises a high repetition frequency laser source, a photoacoustic scanning probe and a molecular imaging device. Through the cooperation of the multi-wavelength fast switching laser and the high-speed scanning probe, synchronous, dynamic and quantitative imaging of vascular function parameters and lymph concentration in a living tissue microenvironment is realized. The system has a video-level imaging rate and can capture a rapid biological process; through coaxial design of dispersion correction and a photoacoustic focus, high spatial resolution and high signal-to-noise ratio of a multispectral image are guaranteed; and the compact probe design realizes large-range scanning. The technology provides a powerful in-vivo visualization tool for research on life science problems such as tumor evolution and drug metabolism.

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.

The invention relates to the technical field of medicinal chemistry, radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a CDK4 / 6-targeted molecular imaging probe labeling precursor, a probe and a preparation method and application thereof. According to the molecular imaging probe [68Ga] Ga-PY03 provided by the invention, on the basis of a Ribociclib structure, a PEG1 chain and proline with envelope conformation are introduced, so that a hydrophobic region in a protein binding pocket can be filled, Van der Waals force can be enhanced, the molecular imaging probe [68Ga] Ga-PY03 can be stably bound with CDK4 / 6, and the targeting of the molecular imaging probe to the CDK4 / 6 is further ensured; the hydrophilicity of the molecular imaging probe can be adjusted, and kidney uptake is reduced; and the compound has excellent tumor / liver and tumor / muscle ratio, and can effectively improve tumor uptake.

The invention relates to the technical field of radiopharmaceutical labeling, in particular to a compound targeting a DDR1 receptor and a radioactive tracer derived from the compound. According to the present invention, the radioactive tracer agent generated after the mixing reaction of the DDR1 receptor targeting compound and the radionuclide has strong receptor binding force with the DDR1 receptor, can accurately position the DDR1 receptor in vivo, has excellent in-vivo targeting performance, and can achieve the tumor molecular imaging purpose through nuclear medicine imaging. The invention relates to a DDR1 receptor targeting compound, which has a structural formula as shown in a formula (I): # imgabs0 # formula (I).

The invention relates to the technical field of optical molecular imaging, in particular to a fluorescent molecular tomography three-dimensional reconstruction system, method and device based on pixel and region integration layering Mama (PR3SM) and a three-dimensional scanning (Tri-scan) mechanism. Aiming at the problems of how to effectively capture global and local spatial characteristics of a fluorescence signal, how to accurately model a radial aggregation and diffusion mode of a fluorescence probe and how to realize a self-adaptive loss function to improve the reconstruction precision, the invention provides a layered three-way scanning Mama fluorescence molecular tomography reconstruction system based on pixel-region integration. The reconstruction precision is improved by introducing a Mama model, the feature modeling capability is enhanced by combining a layered PR-Mama module with a pixel-level SSM and a region-level SSM, forward, backward and spiral center scanning modes are fused through a three-way scanning mechanism, and a fluorophore distribution mode is effectively captured; the adaptive structure senses the loss function, integrates the mean square error and the local structure similarity loss, and improves the adaptability of the loss function.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.

The invention belongs to the technical field of targeting peptides, and particularly relates to an EGFR targeting peptide, a fluorescent probe, a composition and application. The targeting peptide has an amino acid sequence as shown in SEQ ID NO: 1. Through verification, the targeting peptide has the capability of selective enrichment in tumor cells, and is beneficial to tumor recognition and treatment. The fluorescent probe coupled by the targeting peptide and the ICG fluorescent dye can specifically recognize and target an EGFR receptor, realizes effective aggregation and retention at a tumor part, is suitable for targeted diagnosis and treatment of tumors, can realize accurate imaging, has important clinical transformation potential, and becomes a molecular imaging probe with application prospects.

The 18F-labeling of unprotected peptides and sugars via thioarylation using a Au(III)-[˜F]fluoroaryl complex is reported. The chemoselective method generates 18F-labeled S-aryl bioconjugates in an aqueous environment in 15 min with high radiochemical yields and displays excellent functional group tolerance. This approach utilizes an air and moisture stable, robust organometallic Au(III) complex and highlights the versatility of designer organometallic reagents as efficient agents for rapid radiolabeling.

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.

The present invention relates to the technical field of molecular imaging probes, and in particular to a dimer-labeled precursor targeting CXCR4 receptor and a radioactive tracer derived therefrom. 68 Ga]Ga-SDNUM01, a radioactive tracer derived from a precursor labeled for targeting CXCR4 receptor dimer provided by the present invention [ 68 Ga]Ga‑SDNUM04 remained in the tumor for a longer time and showed excellent imaging effect even at 45 minutes.

The present invention belongs to the field of molecular imaging probes for cancer diagnosis, and discloses a nucleic acid aptamer targeting tumor-related calcium channel sensor protein 2 and a molecular imaging probe for diagnosing lung cancer and a preparation method thereof. The nucleic acid aptamer contains 46 nucleotides, can specifically target Trop‑2 on the surface of lung cancer tumor cells, and has a specific targeting recognition effect on lung cancer cells overexpressing Trop‑2, such as non-small cell lung cancer cells H1650, small cell lung cancer cells SBC‑2, etc., and can be used for molecular imaging of Trop‑2 positive lung cancer patients. Molecular imaging probes can be used for non-invasive visual molecular imaging of lung cancer, and have the advantages of high specificity, high sensitivity, good imaging effect, etc. The preparation method of the molecular imaging probe has simple reaction conditions, low cost, and easy clinical transformation.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention provides a molecular probe targeting EDB-FN as well as a preparation method and application of the molecular probe. The structural formula of the molecular probe targeting EDB-FN is shown in the specification, according to the molecular probe targeting EDB-FN, the probe is based on a cyclic peptide probe with Lys-Glu side chain lactam bridge conformation fixed, the connection mode of a DOTA chelating agent is optimized, and the clinical transformation bottlenecks that an existing probe is poor in stability, low in affinity, insufficient in targeting specificity, poor in diagnosis and treatment integration compatibility and the like are solved. The probe can be used for early diagnosis and molecular imaging research of tumors, and provides a reliable basis for tumor malignancy degree evaluation and treatment effect monitoring.

The application relates to the technical field of electronic science and technology, and provides a driving collection controller of a molecular imaging system, which comprises an MCU, a first DAC circuit, a second DAC circuit and a signal conditioning circuit; the MCU converts a first driving signal into a second driving signal through the first DAC circuit to control a first driver; the MCU converts the first driving signal into a third driving signal through the second DAC circuit to control a second driver; and the MCU receives an input signal of an APD or sends a control signal to the APD through the signal conditioning circuit. The first driving signal output by the MCU is converted into the second driving signal and the third driving signal which can be used by different drivers through the first DAC circuit and the second DAC circuit, so that different instruments of the molecular imaging system can be integrated in the driving collection controller for control, the operation is convenient, and the application has good application value.

The present invention belongs to the field of molecular imaging technology and discloses a method, system, device and storage medium for rapid reconstruction of fluorescence molecular tomography. The method excites a specific fluorescent probe through an excitation light source and uses a data acquisition system to obtain light distribution information on the surface of biological tissues. The method constructs a linear relationship between the surface light source distribution and the fluorescent target based on a light transmission model and a finite element method. The linear relationship obtained is converted into an optimization problem to be solved. The optimization problem is quickly solved using an adaptive fast iterative shrinkage threshold algorithm, and the results are displayed to complete the reconstruction. The present invention adopts multi-point excitation and multi-angle measurement, and at the same time combines the light transmission model and the finite element method to establish a linear relationship between the measurement data and the fluorescent target, and converts it into an optimization problem. The adaptive fast iterative shrinkage threshold algorithm is used to quickly solve the optimization problem to be solved, thereby ensuring the reconstruction accuracy while also speeding up the reconstruction speed, effectively improving the efficiency of fluorescence molecular tomography.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.